INC Research CEO reflects on Kendle acquisition

By Gareth Macdonald

- Last updated on GMT

INC Research CEO James Ogle tells that the acquisition of fellow CRO Kendle was about building a presence in emerging trial hotspots and pharmaceutical markets.

The $232m (€165m) acquisition of Kendle earlier​ this month gives INC a presence in Latin America and Asia, broadens its therapeutic reach and provides an expanded customer base according to Ogle.

The key thing here is we are looking at ‘Where is drug development going?’ And, I think the most important thing is that our customers are looking at developing drugs in areas where the ultimately hope to sell them​.”

Ogle also set out INC’s integrations strategy, explaining that the policy is to look for the best person for a particular role “regardless of what legacy part of the business they come from​.”

He also spoke about the firm’s track record of acquisitions – MDS Pharma Services late-stage unit and Trident – and said that while no further takeovers are planned if the correct opportunity arises INC will consider further deals.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers